BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management
Susan Branford(Centre for Cancer Biology), Timothy P. Hughes(South Australia Pathology), Jodi Prime(South Australia Pathology), Dong‐Wook Kim(Catholic University of Korea), Soo-Young Choi(Catholic University of Korea), Jin Eok Park(Catholic University of Korea), David T Yeung(South Australia Pathology), Ju-Hee Bang(Catholic University of Korea), David M. Ross(South Australia Pathology)
Cited by 49
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464